check_circleStudy Completed

Neoplasms

Effect of regorafenib on digoxin and rosuvastatin in patients with advanced solid malignant tumors.

Trial purpose

Evaluate the effect of regorafenib on the pharmacokinetics of digoxin (P-gp substrate : P-glycoprotein) and rosuvastatin (BCRP substrate: Breast cancer resistant protein) by comparing their Area under time curve (AUC(0-24)) and maximum drug concentration (Cmax) on Day -7 and Cycle 1 or Cycle 2 Day 15 of regorafenib in cancer patients

Key Participants Requirements

Sex

Both

Age

18 - N/A

Trial summary

Enrollment Goal
42
Trial Dates
April 2014 - June 2018
Phase
Phase 1
Could I Receive a placebo
No
Products
Stivarga (Regorafenib, BAY73-4506)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Herne, 44625, Germany
Completed
Frankfurt, 60488, Germany
Completed
Freiburg, 79106, Germany
Completed
Budapest, 1083, Hungary
Completed
Budapest, 1122, Hungary

Primary Outcome

  • Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) for Digoxin
    date_rangeTime Frame:
    On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15
    enhanced_encryption
    Safety Issue:
    No
  • Maximum drug concentration (Cmax) in plasma for Digoxin
    date_rangeTime Frame:
    On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15
    enhanced_encryption
    Safety Issue:
    No
  • Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) for rosuvastatin
    date_rangeTime Frame:
    On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15
    enhanced_encryption
    Safety Issue:
    No
  • Maximum drug concentration (Cmax) in plasma for rosuvastatin
    date_rangeTime Frame:
    On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Tumor Response following RECIST criteria
    date_rangeTime Frame:
    From first dose up to 3 months after end of treatment
    enhanced_encryption
    Safety Issue:
    No
  • Number of participants with adverse events as a measure of safety and tolerability
    date_rangeTime Frame:
    Up to 30 days after last dose
    enhanced_encryption
    Safety Issue:
    Yes
  • Number of participants with drug related adverse events as a measure of safety and tolerability
    date_rangeTime Frame:
    Up to 30 days after last dose
    enhanced_encryption
    Safety Issue:
    Yes

Trial design

A Phase I, multi-center, non-randomized, open label, drug-drug-interaction study to determine the effect of multiple doses of regorafenib (BAY 73-4506) on the pharmacokinetics of probe substrates of transport proteins P-gp (digoxin; Group A) and BCRP (rosuvastatin; Group B) in patients with advanced solid malignant tumors
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Non-randomized
Blinding
Open Label
Assignment
Crossover Assignment
Trial Arms
2